Drupanin

Drupanin

SCHEMBL5144749

CC(C)=CCc1cc(C=CC(=O)O)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 13/20 1.00
AKR1B10 O60218 3/20 1.00
AKR1B1 P15121 3/20 1.00
MMP2 P08253 2/20 0.71
PAK1 Q13153 1/20 0.71
AKR1C2 P52895 11/20 0.67
PTPN1 P18031 4/20 0.67
PTGS1 P23219 1/20 0.65
PTGS2 P35354 1/20 0.65
MGAM O43451 1/20 0.61
MAOA P21397 1/20 0.61
MAOB P27338 1/20 0.61
XDH P47989 1/20 0.61
HTT P42858 1/20 0.57
KDM4E B2RXH2 2/20 0.57
HSD17B10 Q99714 2/20 0.57
MEN1 O00255 1/20 0.57
HDAC3 O15379 1/20 0.57
CA12 O43570 1/20 0.57
ALDH1A1 P00352 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Drupanin SCHEMBL3680290 1.00 AKR1C3 (1.00) AKR1C3AKR1B10AKR1B1MMP2PAK1
Drupanin SCHEMBL20472013 0.93 AKR1C3 (0.87) AKR1C3AKR1B10AKR1B1MMP2PAK1
Plicatin B SCHEMBL1227605 0.85 AKR1C3 (0.73) AKR1C3AKR1B10AKR1B1MMP2PAK1
Artepillin SCHEMBL1229229 0.83 AKR1C3 (1.00) AKR1C3AKR1B10AKR1B1MMP2PAK1
Artepillin SCHEMBL2138507 0.83 AKR1C3 (1.00) AKR1C3AKR1B10AKR1B1MMP2PAK1
Artepillin SCHEMBL7128580 0.83 AKR1C3 (1.00) AKR1C3AKR1B10AKR1B1MMP2PAK1
SCHEMBL10632283 0.83 AKR1C3 (0.70) AKR1C3AKR1B10AKR1B1MMP2PAK1
Stipulin SCHEMBL29435847 0.82 PTPN1 (0.88) AKR1C3AKR1B10AKR1B1MMP2PAK1
Stipulin SCHEMBL633709 0.82 PTPN1 (0.88) AKR1C3AKR1B10AKR1B1MMP2PAK1
SCHEMBL30384586 0.82 PTPN1 (0.74) AKR1C3AKR1B10AKR1B1PTPN1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060110520-A1 Active oxygen eliminator derived from natural substance and use thereof MIDORIKAWA KIYOSHI 2006-05-25 US claimed
EP-1621194-A1 ACTIVE OXYGEN ELIMINATOR ORIGINATING IN NATURAL MATERIAL AND USE OF THE SAME Nihon Propolis Co., Ltd. (JP) 2006-02-01 EP claimed
US-20230226003-A1 NATURAL ANTIBACTERIAL AND ANTIVIRAL BIOLOGICAL COMPOSITIONS, COMPOUNDS, METHOD FOR OBTAINING SAME, AND USE THEREOF BEEOTEC HOLDING S/A (BR) 2023-07-20 US disclosed
CN-115942943-A Natural antibacterial and antiviral biological compositions, compounds, methods of obtaining and uses thereof 贝奥泰科控股股份有限公司 2023-04-07 CN disclosed
EP-4154895-A2 NATURAL ANTIBACTERIAL AND ANTIVIRAL BIOLOGICAL COMPOSITIONS, COMPOUNDS, METHOD FOR OBTAINING SAME, AND USE THEREOF Beeotec Holding S/A (BR) 2023-03-29 EP disclosed
EP-1621194-A4 ACTIVE OXYGEN ELIMINATOR ORIGINATING IN NATURAL MATERIAL AND USE OF THE SAME NIHON PROPOLIS CO LTD (JP) 2007-01-10 EP disclosed
US-20060110520-A1 Active oxygen eliminator derived from natural substance and use thereof MIDORIKAWA KIYOSHI 2006-05-25 US disclosed
US-20060110520-A1 Active oxygen eliminator derived from natural substance and use thereof MIDORIKAWA KIYOSHI 2006-05-25 US disclosed
EP-1621194-A1 ACTIVE OXYGEN ELIMINATOR ORIGINATING IN NATURAL MATERIAL AND USE OF THE SAME Nihon Propolis Co., Ltd. (JP) 2006-02-01 EP disclosed
EP-1621194-A1 ACTIVE OXYGEN ELIMINATOR ORIGINATING IN NATURAL MATERIAL AND USE OF THE SAME Nihon Propolis Co., Ltd. (JP) 2006-02-01 EP disclosed
EP-1575689-A2 TYPING NATURAL PRODUCTS Marcucci Ribeiro, Maria Cristina (BR) 2005-09-21 EP disclosed
WO-2005067918-A1 ACTIVE OXYGEN ELIMINATOR ORIGINATING IN NATURAL MATERIAL AND USE OF THE SAME NIHON PROPOLIS CO., LTD. (JP) 2005-07-28 WO disclosed
JP-2005200360-A ACTIVE OXYGEN SCAVENGER DERIVED FROM NATURAL PRODUCT AND APPLICATION THEREOF NIPPON PUROPORISU KK 2005-07-28 JP disclosed
US-20040126437-A1 Typing natural products RIBEIRO MARIA CRISTINA MARCUCC (BR) 2004-07-01 US disclosed
WO-2002051516-A2 TYPING NATURAL PRODUCTS MARCUCCI RIBEIRO MARIA CRISTIN (BR) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226003-A1 NATURAL ANTIBACTERIAL AND ANTIVIRAL BIOLOGICAL COMPOSITIONS, COMPOUNDS, METHOD FOR OBTAINING SAME, AND USE THEREOF NEFM, TNF, POLM AKR1C3 4262/4885AKR1B10 3786/4885AKR1B1 4172/4885
US-20040126437-A1 Typing natural products ACHE, BCHE, HLA-C AKR1C3 429/4885AKR1B10 807/4885AKR1B1 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.